{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:49:06Z","timestamp":1792363746560,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.mayocp.2015.04.016","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T13:07:40Z","timestamp":1436360860000},"page":"1116-1124","source":"Crossref","is-referenced-by-count":34,"title":["Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases"],"prefix":"10.1016","volume":"90","author":[{"given":"Herbert L.","family":"DuPont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2015.04.016_bib1","unstructured":"Xifaxan (rifaximin) tablets [package insert]. Raleigh, NC: Salix Pharmaceuticals;\u00a02014."},{"issue":"2","key":"10.1016\/j.mayocp.2015.04.016_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/14656566.2011.546347","article-title":"Biologic properties and clinical uses of rifaximin","volume":"12","author":"DuPont","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.mayocp.2015.04.016_bib3","first-page":"51","article-title":"Pharmacokinetic study of rifaximin after oral administration in healthy volunteers","volume":"14","author":"Descombe","year":"1994","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.mayocp.2015.04.016_bib4","unstructured":"Travelers\u2019 diarrhea. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/ncidod\/dbmd\/diseaseinfo\/travelersdiarrhea_g.htm. Published November 21, 2006. Accessed October 29,\u00a02014."},{"issue":"9","key":"10.1016\/j.mayocp.2015.04.016_bib5","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/jama.1983.03330330054035","article-title":"Epidemiology of diarrhea in travelers","volume":"249","author":"Steffen","year":"1983","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.mayocp.2015.04.016_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4269\/ajtmh.2009.80.609","article-title":"Global etiology of travelers\u2019 diarrhea: systematic review from 1973 to the present","volume":"80","author":"Shah","year":"2009","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.mayocp.2015.04.016_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2036.2009.04028.x","article-title":"Systematic review: the epidemiology and clinical features of travellers\u2019 diarrhoea","volume":"30","author":"DuPont","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2015.04.016_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/jtm.12049","article-title":"Post-infectious sequelae of travelers' diarrhea","volume":"20","author":"Connor","year":"2013","journal-title":"J\u00a0Travel Med"},{"issue":"6","key":"10.1016\/j.mayocp.2015.04.016_bib9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1159\/000007580","article-title":"Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers\u2019 diarrhea","volume":"59","author":"DuPont","year":"1998","journal-title":"Digestion"},{"issue":"11","key":"10.1016\/j.mayocp.2015.04.016_bib10","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1086\/323814","article-title":"Rifaximin versus ciprofloxacin for the treatment of traveler\u2019s diarrhea: a randomized, double-blind clinical trial","volume":"33","author":"DuPont","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.mayocp.2015.04.016_bib11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.4269\/ajtmh.2006.74.1060","article-title":"A\u00a0randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers\u2019 diarrhea","volume":"74","author":"Taylor","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"10.1016\/j.mayocp.2015.04.016_bib12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/0003-4819-142-10-200505170-00005","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers\u2019 diarrhea","volume":"142","author":"DuPont","year":"2005","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2015.04.016_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1708-8305.2009.00385.x","article-title":"Prevention of travelers\u2019 diarrhea with rifaximin in US travelers to Mexico","volume":"17","author":"Martinez-Sandoval","year":"2010","journal-title":"J\u00a0Travel Med"},{"issue":"2","key":"10.1016\/j.mayocp.2015.04.016_bib14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.mayocp.2015.04.016_bib15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMe1000850","article-title":"Gut flora and hepatic encephalopathy in patients with cirrhosis","volume":"362","author":"Riordan","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2015.04.016_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1586\/17474124.2014.858598","article-title":"Recent insights into the pathogenesis of hepatic encephalopathy and treatments","volume":"8","author":"Sturgeon","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"46","key":"10.1016\/j.mayocp.2015.04.016_bib17","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.3748\/wjg.v18.i46.6693","article-title":"Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota","volume":"18","author":"Garcovich","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.mayocp.2015.04.016_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrgastro.2010.116","article-title":"Mechanisms, diagnosis and management of hepatic encephalopathy","volume":"7","author":"Prakash","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.mayocp.2015.04.016_bib19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhep.2014.09.005","article-title":"Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure","volume":"62","author":"Romero-G\u00f3mez","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.mayocp.2015.04.016_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/apt.12803","article-title":"Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy","volume":"40","author":"Kimer","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.mayocp.2015.04.016_bib21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2015.04.016_bib22","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.cgh.2013.12.021","article-title":"Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy","volume":"12","author":"Mullen","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.04.016_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jgh.12070","article-title":"Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis","volume":"28","author":"Vlachogiannakos","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.mayocp.2015.04.016_bib24","first-page":"1910","article-title":"The epidemiology of irritable bowel syndrome in North America: a systematic review","volume":"97","author":"Saito","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.mayocp.2015.04.016_bib25","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.mayocp.2015.04.016_bib26","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","article-title":"Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact","volume":"21","author":"Hungin","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2015.04.016_bib27","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2015.04.016_bib28","first-page":"S1","article-title":"An evidence-based position statement on the management of irritable bowel syndrome","volume":"104","author":"Brandt","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"17","key":"10.1016\/j.mayocp.2015.04.016_bib29","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJMra1207068","article-title":"Peripheral mechanisms in irritable bowel syndrome","volume":"367","author":"Camilleri","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2015.04.016_bib30","unstructured":"Moleski SM. Irritable bowel syndrome (IBS) (spastic colon). Merck website. http:\/\/www.merckmanuals.com\/home\/digestive_disorders\/irritable_bowel_syndrome_ibs\/irritable_bowel_syndrome_ibs.html?qt=irritable%20bowel%20syndrome&alt=sh. Updated August 2013. Accessed January 22,\u00a02015."},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2015.04.016_bib31","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2014.187","article-title":"American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.mayocp.2015.04.016_bib32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2015.04.016_bib33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","article-title":"A\u00a0randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence","volume":"101","author":"Sharara","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mayocp.2015.04.016_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CEG.S18051","article-title":"High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome","volume":"4","author":"Jolley","year":"2011","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.04.016_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2015.04.016_bib36","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s10620-011-1728-5","article-title":"Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects","volume":"56","author":"Pimentel","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.mayocp.2015.04.016_bib37","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1007\/s10620-011-1889-2","article-title":"Long-term outcome of rifaximin therapy in non-constipation irritable bowel syndrome","volume":"56","author":"Weinstock","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"15","key":"10.1016\/j.mayocp.2015.04.016_bib38","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3748\/wjg.v18.i15.1723","article-title":"Epidemiology and clinical course of Crohn\u2019s disease: results from observational studies","volume":"18","author":"Hovde","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mayocp.2015.04.016_bib39","unstructured":"Walfish AE, Sachar DB. Crohn disease. Merck website. http:\/\/www.merckmanuals.com\/home\/digestive_disorders\/inflammatory_bowel_diseases_ibd\/crohn_disease.html?qt=crohn&alt=sh. Updated April 2013. Accessed January 22,\u00a02015."},{"key":"10.1016\/j.mayocp.2015.04.016_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/CEG.S41413","article-title":"Measuring disease activity in Crohn\u2019s disease: what is currently available to the clinician","volume":"7","author":"D\u2019Inc\u00e0","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"issue":"8","key":"10.1016\/j.mayocp.2015.04.016_bib41","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1185\/030079905X53252","article-title":"An open-label evaluation of rifaximin in the treatment of active Crohn\u2019s disease","volume":"21","author":"Shafran","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.mayocp.2015.04.016_bib42","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1365-2036.2006.02879.x","article-title":"Antibiotic treatment of Crohn\u2019s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin","volume":"23","author":"Prantera","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2015.04.016_bib43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.gastro.2011.11.032","article-title":"Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn\u2019s disease","volume":"142","author":"Prantera","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.mayocp.2015.04.016_bib44","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1128\/AAC.00691-09","article-title":"Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles","volume":"54","author":"Brown","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.mayocp.2015.04.016_bib45","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s10620-013-2675-0","article-title":"The effect of rifaximin on gut flora and Staphylococcus resistance","volume":"58","author":"Kim","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1016\/j.mayocp.2015.04.016_bib46","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/AAC.00161-10","article-title":"Bile acids improve the antimicrobial effect of rifaximin","volume":"54","author":"Darkoh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.mayocp.2015.04.016_bib47","doi-asserted-by":"crossref","first-page":"e60042","DOI":"10.1371\/journal.pone.0060042","article-title":"Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy","volume":"8","author":"Bajaj","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mayocp.2015.04.016_bib48","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4161\/gmic.25723","article-title":"Cirrhosis, bile acids, and gut microbiota: unraveling a complex relationship","volume":"4","author":"Ridlon","year":"2013","journal-title":"Gut Microbes"},{"issue":"2","key":"10.1016\/j.mayocp.2015.04.016_bib49","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","article-title":"Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats","volume":"146","author":"Xu","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mayocp.2015.04.016_bib50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000068362","article-title":"Inhibition of intestinal bacterial translocation with rifaximin modulateslamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis","volume":"66","author":"Fiorucci","year":"2002","journal-title":"Digestion"},{"issue":"8","key":"10.1016\/j.mayocp.2015.04.016_bib51","doi-asserted-by":"crossref","first-page":"G529","DOI":"10.1152\/ajpgi.00207.2012","article-title":"Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome","volume":"305","author":"Ringel","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"10","key":"10.1016\/j.mayocp.2015.04.016_bib52","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/apt.12728","article-title":"Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets","volume":"39","author":"DuPont","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"39","key":"10.1016\/j.mayocp.2015.04.016_bib53","doi-asserted-by":"crossref","first-page":"14105","DOI":"10.3748\/wjg.v20.i39.14105","article-title":"Irritable bowel syndrome: a microbiome-gut-brain axis disorder?","volume":"20","author":"Kennedy","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.04.016_bib54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/jpet.110.170225","article-title":"Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation","volume":"335","author":"Cheng","year":"2010","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2015.04.016_bib55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2004.04.019","article-title":"Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes","volume":"127","author":"Langmann","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2015.04.016_bib56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.gastro.2005.12.008","article-title":"The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease","volume":"130","author":"Dring","year":"2006","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mayocp.2015.04.016_bib57","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1053\/j.gastro.2010.10.036","article-title":"Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis","volume":"139","author":"Sartor","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.mayocp.2015.04.016_bib58","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3748\/wjg.v19.i5.648","article-title":"Use of antibiotics in the treatment of Crohn\u2019s disease","volume":"19","author":"Scribano","year":"2013","journal-title":"World J Gastroenterol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961500350X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961500350X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T02:50:29Z","timestamp":1566960629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561961500350X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S002561961500350X"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2015.04.016","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}